Latest Headlines

Latest Headlines

Self-healing hydrogel and ultrasound combo allows for 'on demand' delivery

Harvard University researchers have developed a system for releasing high doses of drugs in short bursts using ultrasound and self-healing hydrogel. Future therapy could therefore be highly customized and locally delivered at specific times, as opposed to the dominant sustained release paradigm.   

Bristol-Myers wraps nivolumab PhIII cancer trial early on promising survival benefit

Bristol-Myers Squibb claimed bragging rights to the first batch of Phase III data on an immuno-oncology drug that clearly demonstrated an improvement over a standard therapy for overall survival.

InVivo Therapeutics to ax hydrogel drug delivery program, cutting jobs

InVivo Therapeutics announced June 19 that it is terminating its preclinical hydrogel drug delivery program as the company focuses on its investigational devices for spinal cord injury, the Neuro-Spinal Scaffold and the Neuro-Spinal Scaffold Plus Stem Cells.

R&D spending rebounds big in 2013

Pharma companies have taken some heat for their R&D productivity levels as of late, but drug developers and investors may recently have seen some of their faith restored.

Biotechs queue up for $269M in fresh IPOs amid a sector rebound

Four more drug developers are angling to make Wall Street debuts, lining up to raise a combined $269 million as the market for biotech IPOs has shown renewed signs of life after a tepid spring.

EY: R&D budgets soar as cash-laden biotechs spend big on research

While the world's biopharma players are still working to solve the problem of R&D productivity, they're hardly being stingy in the process. R&D spending across the industry leapt 14% last year, according to EY, a sharp rebound reflecting renewed optimism among drug developers and their investors.

New device uses smartphone to diagnose adrenal gland diseases

Smartphone technology is picking up steam as a viable diagnostic tool, and a new device that uses the technology could help physicians diagnose and monitor adrenal gland diseases.

Flying alert device, ingested drug sensor and bionic suit may be the future of med tech

What's the future of med tech? Here's a look at some of the most outlandish and perhaps forward-thinking devices in the works.

Isis is in the spotlight--and maybe crosshairs--after gene breakthrough

Antisense specialist Isis Pharmaceuticals has made it all the way to mid-stage trials with ISIS-APOCIII, targeting patients with a rare ailment that leads to dangerously high triglycerides. But that candidate is looking all the more promising in light of two major studies linking its target to reduced rates of heart attack, saddling the biotech with a potential blockbuster.

Bristol-Myers toes the next hep C frontier: a four-week cure

Gilead Sciences' Sovaldi has broken sales records thanks to its ability to cure hepatitis C with an effective, if costly, 12-week regimen. But rivals believe there's plenty of room in the market for a speedier solution, and Bristol-Myers Squibb plans to use its ex-partner's blockbuster to craft a four-week contender.